ArticleThe Pan African medical journal2025
The African measles and rubella laboratory network: 21 years of functioning in West Africa.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO (World Health Organization) African Region measles/rubella laboratory network was established to provide support to the measles/rubella elimination program. From the official designation of a laboratory to the provision of basic equipment and training, regular laboratory assessment, the network has been functioning for more than 21 years in a standardized manner. We analyzed the performance of the laboratory network in the Western Africa Subregion. The comparison of the period 2004-2013 versus the period 2014-2024 shows an increase in the average number of functioning laboratories, specimens received /tested and onsite accreditation reviews conducted. The overall timeliness in sending out IgM results to EPI/national level remains above the expected target. Quarterly confirmatory testing for serology is implemented by most of the laboratories. More than 92% of the laboratories have obtained a passing score for annual serology Proficiency Test. With the molecular tests taking place in laboratories that have passed the molecular external quality assurance test, measles B3 genotypes were identified in 11 countries of the sub-Region over the past 21 years. As of today, the measles and rubella laboratory network in West Africa continues to operate despite the various challenges faced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.